




**Rebalance the autonomic nervous system.  
Improve heart failure symptoms.**

# Barostim is an option to improve exercise capacity in the 72% of patients not indicated for CRT

GDMT improves heart failure mortality and morbidity in HFrEF patients, but only shows modest improvement in exercise capacity.<sup>1</sup>



## Barostim rebalances the autonomic nervous system and improves heart failure symptoms

Barostim works by electrically stimulating carotid baroreceptors which increases baroreceptor signaling, rebalances the autonomic nervous system and improves heart failure symptoms.


	Heart failure	Barostim
Baroreceptor signaling	↓ <sup>5</sup>	↑ <sup>7</sup>
Sympathetic tone	↑ <sup>6</sup>	↓ <sup>7</sup>
Parasympathetic tone	↓ <sup>6</sup>	↑ <sup>8</sup>
Heart failure symptoms	↑ <sup>6</sup>	↓ <sup>3</sup>




# Sustained symptomatic improvements

Barostim plus GDMT provides significant and meaningful improvements for heart failure patients beyond GDMT alone


## Exercise capacity (6MHW)<sup>9</sup>




## Quality of life (MLWHF)<sup>9</sup>



## Functional status (NYHA Class)<sup>9</sup>




## Freedom from all-cause death, LVAD or transplant<sup>9</sup>



## Safe implant procedure

The Barostim System is implanted in a safe surgical procedure where the Carotid Sinus Lead is sutured to the carotid sinus and the Barostim NEO™ IPG is inserted in a standard device pocket.

The system contains no hardware in the heart or vasculature.



Freedom from major adverse neurological or cardiovascular system or procedure-related event rate in the Barostim arm<sup>9</sup>

## Indications

- NYHA Class III despite treatment with guideline-directed medical therapies (medications and devices)\*
- LVEF  $\leq$  35%



\* Guideline directed medical therapy according to AHA/ACC/ESC guidelines

1. Lewis G et al. *Circ Heart Fail.* 2022 May; 15(5):510-524; 2. Abraham WT, Zile MR et al. *JACC: Heart Failure* 2015 June; 3(6):487-496; 3. Zile MR, et al. *J Am Coll Cardiol* 2020; 76:1-13; 4. McDonagh TA et al, *European Heart Journal* (2021) 42, 3427[1]3520; Class I and Class IIa recommendations; 5. Creager MA, Creager SJ. *J Am Coll Cardiol.* 1994;23(2):401-5; 6. Mortara A. *Circulation.* 1997;96:3450-3458; 7. Gronda, E, et al. *European Journal of Heart Failure* 16.9 (2014): 977-983; 8. Wustmann et al. *Hypertension* 2009 Sep;54(3):530-6; 9. Instructions for Use 900133-001 Rev. D available at [www.cvr.com/ifu](http://www.cvr.com/ifu); 10. Gremeaux V, et al. *Arch Phys Med Rehabil.* 2011;92(4):611-619.; 11. Rector TS, et al. *J Card Fail.* 1995;1(3):201-216.

The Barostim™ System is CE Marked and approved for sale for heart failure patients and hypertension patients in the European Union (EU).

For a complete listing of all risks and benefits, please visit [www.cvr.com/benefit-risk-analysis](http://www.cvr.com/benefit-risk-analysis). For a list of all applicable patents, see [www.cvr.com/patent-marking](http://www.cvr.com/patent-marking).

CVRx, Barostim, BAT, Barostim NEO, Barostim NEO2, BATwire, Outsmart the heart, and Barohub are all trademarks of CVRx, Inc.  
© 2024 CVRx, Inc. All rights reserved. All other trademarks are property of their respective owners.

**CVRx**  
Outsmart the heart

CVRx, Inc.  
9201 West Broadway Avenue, Suite 650  
Minneapolis, MN 55445 USA  
P 763-416-2840 | F 763-416-2841  
[cvrx.eu](http://cvrx.eu)

950385-002